课题基金 / 基金详情

12/15-Lipoxygenase and neurovascular damage following cardiac arrest

12/15-Lipoxygenase and neurovascular damage following cardiac arrest
心脏骤停后的 12/15-脂氧合酶和神经血管损伤
批准号:
8239055
负责人:
KLAUS VAN LEYEN
金额:
$37.67万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2016-05-31

项目摘要

项目成果

KLAUS VAN LEYEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ischemic brain damage is a major factor contributing to high rates of both disability and mortality following heart failure. Cardiac arrest leads to selective cell death in both hippocampus and cortex, as well as vascular leakage and edema. Oxidative stress is a major feature of ischemic brain damage, and 12/15-lipoxygenase (12/15-LOX) is one of its main mediators. In this proposal, we plan to investigate the contributions of 12/15- LOX to both vascular damage and neuronal cell death following global ischemia induced by cardiac arrest. We have previously established 12/15-LOX as a major contributor to delayed neuronal cell death and leakage of the blood - brain barrier following transient focal ischemia. In addition, we have elucidated a major cell death pathway centered on 12/15-LOX. Here, we will use mouse models of cardiac arrest and global cerebral ischemia to investigate increased 12/15-LOX expression after cardiac arrest. Our central hypothesis states that increased vascular and neuronal 12/15-LOX exacerbates brain damage by causing oxidative stress, leading to vascular leakage, edema, and the death of neurons. Our preliminary results show that a) expression of 12/15-LOX is increased in a mouse model of cardiac arrest and resuscitation; b) 12/15-LOX co-localizes with MDA2, a marker for oxidative stress, as well as FluoroJade B, a marker for cellular injury; c) these findings can be replicated in a model of global cerebral ischemia; and d) mice in which 12/15-LOX has been genetically deleted show reduced damage after cardiac arrest. We propose to study the consequences of 12/15-LOX up-regulation in mouse models of global ischemia in the following specific aims. In Aim 1, we characterize the expression of 12/15-LOX in a mouse model of cardiac arrest with resuscitation. Besides determining the cell types expressing 12/15-LOX, we will investigate markers of oxidative stress and cellular damage. In addition, we will measure levels of edema and vascular leakage. In Aim 2, we study the protection through 12/15-LOX gene knockout against neural cell death and edema formation in the mouse model of cardiac arrest and resuscitation. In Aim 3, we investigate the protective potential of pharmacologically inhibiting 12/15-LOX with a specific inhibitor, and compare with therapeutic hypothermia treatment. We will determine both short- and long-term outcome, using behavioral tests and histological measures. Severe ischemia and reperfusion injury is associated with cardiac arrest and subsequent cardiopulmonary resuscitation. Elucidating the role of 12/15-LOX in mediating ischemic damage may lead to novel therapeutic options in treating cardiac arrest patients. PUBLIC HEALTH RELEVANCE: Oxidative stress and damage to the brain vasculature are major complications in the aftermath of cardiac arrest, leading to the death of neurons and edema in the brain. 12/15-Lipoxygenase is one of the major mediators of oxidative stress, and we propose to study its role in causing brain injury following cardiac arrest and global brain ischemia. By blocking the activity of 12/15-lipoxygenase, we hope to find new treatment options that benefit survivors of cardiac arrest.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Neuroprotectant to Reduce Ischemic Injury
  • 批准号:
    10576568
  • 项目类别:
  • 资助金额:
    $40.84万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network
  • 批准号:
    10671991
  • 项目类别:
  • 资助金额:
    $33.85万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Development of human 12/15-lipoxygenase therapeutics for stroke
  • 批准号:
    9898504
  • 项目类别:
  • 资助金额:
    $66.96万
  • 财政年份:
    2018
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Development of human 12/15-lipoxygenase therapeutics for stroke
  • 批准号:
    9922389
  • 项目类别:
  • 资助金额:
    $66.15万
  • 财政年份:
    2018
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
海外基金